Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (CONVERT)
End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis
About this trial
This is an interventional treatment trial for End-stage Renal Disease focused on measuring End-stage renal disease (ESRD), Hemodialysis
Eligibility Criteria
Inclusion Criteria:
- Participants must be at least 18 years of age
- Patients with end-stage renal disease on hemodialysis (including hemodiafiltration) for ≥3 months, receiving dialysis at least 9 hours a week and stable in the view of the investigator
- Body weight of at least 50 kg
- Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Recent (<6 months before screening) clinically significant bleeding
- Hemoglobin (Hb) < 9.0 g/dL at screening
- Platelet count < 100 x 109/L
- aPTT or PT > ULN (upper limit of normal)
- Hepatic disease associated with ALT > 3x ULN, or total bilirubin >2x ULN with direct bilirubin > 20% of the total
- Sustained uncontrolled hypertension (diastolic blood pressure ≥100 mmHg and/or systolic blood pressure ≥ 180 mmHg)
- Known intracranial neoplasm, arteriovenous malformation or aneurysm
- Known bleeding disorders e.g. von-Willebrand disease or Hemophilia A, B or C
- Recent (<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke or VTE (except dialysis access thrombosis)
- Recent (<3 months before screening) major surgery or scheduled major surgery during study participation
- Scheduled living donor renal transplant during study participation
- Persistent heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher
- Receiving antiplatelet therapy except daily ASA ≤ 150 mg/day
- Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure
Sites / Locations
- North America Research Institute - Azusa
- Fresenius Kidney Care - Brawley
- DaVita South Valley Dialysis
- Fresenius Kidney Care - La Mesa
- East L.A. Dialysis Center
- Van Buren Dialysis Center
- Fresenius Kidney Care Kearny Mesa
- FMC San Ysidro
- Queen's Dialysis Unit
- DaVita Greater Waterbury Dialysis
- ARA Plantation Dialysis, LLC
- ARA Augusta
- Liberty Dialysis- Caldwell
- Fresenius Kidney Care Evergreen Park
- Fresenius Kidney Care Baton Rouge Mancuso Lane
- Fresenius Kidney Care South Dialysis
- ARA Holyoke Dialysis Center
- Davita Hospital Hill Dialysis
- Renal Medicine Associates
- Durham Nephrology Associates, Pa
- Waterloo Dialysis
- Fresenius North Austin Dialysis Center
- Fresenius Kidney Care - Mission Bend (FMCNA #3971)
- Fresenius Kidney Care Sugar Land
- Liberty Dialysis St. George
- DaVita Butler Farm Dialysis
- Sydney Adventist Hospital
- Westmead Hospital
- Eastern Health Integrated Renal Service
- John Hunter Hospital
- Klinikum Klagenfurt am Wörthersee
- Privatklinik Wehrle-Diakonissen
- Klinik Landstraße - Krankenhaus Rudolfstiftung
- Universitätsklinikum AKH Wien
- Epicura
- Imeldaziekenhuis - St-Elisabethkliniek
- AZ St-Lucas Campus St-Lucas
- UZ Leuven Gasthuisberg
- CHU de Liege | CHR Citadel - Department of Nephrology
- AZ Nikolaas Campus Sint-Niklaas
- MHAT Sveti Ivan Rilski 2003
- MHAT Haskovo
- UMHAT Kanev AD
- MHAT Shumen AD
- Multiprofile Hospital for Active Treatment Hristo Botev AD
- Krajska Nemocnice Liberec
- Fakultni nemocnice Ostrava
- Privamed s.r.o.
- Fresenius Nephro Care s.r.o. - Sokolov
- General Hospital of Arta
- HIPPOKRATION General Hospital of Athens
- General Hospital of Athens LAIKO
- Ioannina University General Hospital
- University General Hospital of Larissa
- Hippokration General Hospital of Thessaloniki
- General Hospital of Thessaloniki Papageorgiou
- Bajai Szent Rokus Korhaz
- Fresenius Medical Care Egeszsegugyi Kft.
- Eszak-Pesti Centrumkorhaz-Honvedkorhaz
- Csongrad Megyei Egeszsegugyi Ellato Kozpont,Hodmezovasarhely
- Keszthelyi Korhaz
- Fresenius Medical Care Egeszsegugyi Kft.
- Fresenius Medical Care Egeszsegugyi Kft.
- Barzilai Medical Center | Nephrology & Hypertension Dept.
- Lady Davis Carmel Medical Center
- Health Corporation of Galilee Medical Center
- Rabin Medical Center, HaSharon (Golda) Campus
- Clalit Health Services Rabin Medical Center-Beilinson Campus
- Poriya Medical Center | Nephrology and Hypertension Dept.
- Shamir Medical Center (Assaf Harofeh)
- A.O.U. di Bologna Policlinico S.Orsola Malpighi
- A.O.U. di Parma
- AUSL-IRCCS di Reggio Emilia
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- IRCCS Ospedale Policlinico San Martino
- IRCCS Istituti Clinici Scientifici Maugeri SpA SB
- A.O.U. Careggi
- Ibaraki Seinan Medical Center Hospital
- Tsuchiura Beryl Clinic
- Ohishi Naika Clinic
- Kikuchi Medical Clinic
- Katta General Hospital
- Nagaoka Red Cross Hospital
- Saiyu Clinic
- Takemura Medical Nephro Clinic
- Futakotamagawaekimae clinic
- Saint Hill Hospital
- Akebono Clinic
- Kyoto Station Takeda Dialysis Clinic
- Akagaki Clinic
- Yabuki Hospital
- LUHS Kauno Hospital (Josvainiu str.)
- Academisch Medisch Centrum (AMC)
- Gelre Ziekenhuizen
- Deventer Ziekenhuis
- Albert Schweitzer Ziekenhuis, Dordwijk
- Catharina Ziekenhuis
- Maasstad Ziekenhuis | Neurology Department
- Wojewodzki Szpital Zespolony
- Stacja Dializ Olkusz
- NZOZ Nowy Szpital w Swieciu Sp. z o.o.
- Stacja Dializ W-wa Mangalia
- Stacja Dializ Zyrardow
- Eurodial Obidos (DaVita)
- SPD - Amadora (Diaverum Amadora)
- CHLO - Hospital Santa Cruz
- Pluribus Dialise - Cascais (DaVita)
- Pluribus Dialise - Sacavem (DaVita)
- Caledial - Centro de Hemodialise de Gaia
- Centro Hospitalar do Medio Tejo | Unidade de Torres Novas - Nephrology Department
- Diaverum Aveiro
- Eurodial Leiria (DaVita)
- NephroCare APDP
- Chelyabinsk Regional Clinical Hospital
- LLC Dialysis center
- LLC Fresenius medical care Kuban
- LLC Dialysis center
- City Clinical Hospital #1 Orenburg
- Republican Hospital n.a. V.A. Baranov
- Kupchinsky center for outpatient dialysis
- LLC B. Brown Avitum Russland Clinics
- City Hospital #31
- LLC Yaroslavl dialysis center
- Sverdlovsk Regional Clinical Hospital #1
- Hospital Clínico Universitario de Santiago de Compostela
- Hospital Universitari Germans Trias i Pujol
- Hospital Althaia, Xarxa Assistencial de Manresa
- Corporació Sanitària Parc Taulí
- Hospital Clinico Universitario San Carlos | Nefrologia
- Hospital Clínico Universitario de Valencia
- Hospital Universitario Dr. Peset
- Hacettepe Universitesi Tip Fakultesi
- Adnan Menderes Universitesi Tip fakultesi
- Turk Bobrek Vakfi Memorial Hizmet Hastanesi
- Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi
- Erciyes Universitesi Tip Fakultesi
- Kocaeli Universitesi Tip Fakultesi
- Inonu Universitesi Tip Fakultesi
- Brovarskaya multidisciplinary clinical hospital
- Medical center LLC " Fresenius medical care Ukraine"
- Dnepropetrovsk regional hospital n.a. I. I. Mechnikov
- Regional Clinical Hospital - Ivano-Frankivsk
- Kharkiv regional Clinical Centre of urology and nephrology
- Kyiv City Center of Nephrology and Dialysis
- State Institution "Institute of Nephrology" NAMS of Ukraine
- Lutsk city clinical hospital
- Mykolaiv Regional Clinical Hospital
- Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi
- Transcarpatian Regional Clinical Hospital
- Vinnitsa Regional Clinical Hospital im. N.I. Pirogov
- Zaporizhzhia Regional Clinical Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Experimental
BAY1213790 low dose
Placebo low dose
BAY1213790 high dose
Placebo high dose
Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
Placebo will be administered subcutaneously in the same manner as Osocimab.
Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
Placebo will be administered subcutaneously in the same manner as Osocimab.